(Q36634599)

15 August 2017

1 reference

title

Update on risk-stratified management for chronic lymphocytic leukemia (English)

1 reference

15 August 2017

0 references

4

Tait D Shanafelt

1 reference

15 August 2017

2

Timothy G Call

1 reference

15 August 2017

1

Clive S Zent

1 reference

15 August 2017

5

Neil E Kay

1 reference

15 August 2017

William J Hogan

3

1 reference

15 August 2017

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

47

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

1738-1746

1 reference

Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Stem cell transplantation for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

How I treat refractory CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Vaccination against infections in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Salvage therapy for CLL and the role of stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

When and how to treat chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

Solid tumors after chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600634036

10.1080/10428190600634036

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference